ReviewTargeted oncology2011
Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences.
Review in Targeted oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- mTOR Signaling as a Regulator of Hematopoietic Stem Cell Fate.Stem cell reviews and reports · 2021Review
- Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpoint.Nucleic acids research · 2021Article
- Autophagy in hypoxic ovary.Cellular and molecular life sciences : CMLS · 2019Review
- Ambiguous Effects of Autophagy Activation Following Hypoperfusion/Ischemia.International journal of molecular sciences · 2018Review
- mTOR Pathways in Cancer and Autophagy.Cancers · 2018Review
- The resolution of ambiguity as the basis for life: A cellular bridge between Western reductionism and Eastern holism.Progress in biophysics and molecular biology · 2017Review
- Heterogenous ribonucleoprotein A18 (hnRNP A18) promotes tumor growth by increasing protein translation of selected transcripts in cancer cells.Oncotarget · 2016Article
- Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.Breast cancer : basic and clinical research · 2014Article
- Hypoxia induces permeability and giant cell responses of Andes virus-infected pulmonary endothelial cells by activating the mTOR-S6K signaling pathway.Journal of virology · 2013Article
- DDIT4/REDD1/RTP801 is a novel negative regulator of Schwann cell myelination.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013Article
- Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor C sensitive.Journal of virology · 2012Article
- DEPTOR ubiquitination and destruction by SCF(β-TrCP).American journal of physiology. Endocrinology and metabolism · 2012Review
- Are we ready to move away from nature?: the rapamycin story.Targeted oncology · 2011Article
- Targeting the target of rapamycin (TOR): looking to mother nature.Targeted oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Integration of cellular and extracellular signals maintains tissue homeostasis under conditions of normal proliferation and stress. A central player in regulating responses to stress is the serine/threonine kinase mammalian target of rapamycin (mTOR). In many cancers, mTOR complex 1 (mTORC1) signaling is enhanced, even under conditions where such signaling should be suppressed. This article reviews some of the details that are emerging on how low oxygen (hypoxia) regulates mTORC1 signaling, and the consequences for dysregulation in pediatric solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.